Placebo News and Research

RSS

Love hormone may enhance pleasure of social interactions, UCI study finds

The hormone oxytocin, which has been associated with interpersonal bonding, may enhance the pleasure of social interactions by stimulating production of marijuana-like neurotransmitters in the brain, according to a University of California, Irvine study.

27 Oct 2015

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

26 Oct 2015

Common steroid medication does not reduce risk of long-term pain after heart surgery

A common steroid medication does not ease long-term pain at the incision site made during open-heart surgery, according to results of a large multicenter randomized controlled trial being presented at the ANESTHESIOLOGY 2015 annual meeting.

26 Oct 2015

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Evidence is mounting that drugs used to treat depression and Alzheimer's disease also can help patients recover from strokes. But there are conflicting findings from studies of these and other drugs given to recovering stroke patients.

22 Oct 2015

Major UK trial to examine role of aspirin in cancer recurrence

The world's largest ever clinical trial looking at whether taking aspirin every day stops some of the most common cancers coming back, launches across the UK today (Thursday).

22 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Leading obesity groups stress need to regulate weight-loss dietary supplements

On the heels of a new study tying dietary supplements to more than 23,000 emergency room visits each year, four leading obesity research, treatment and prevention groups issue a joint scientific statement recommending dietary supplements for weight loss claiming curative or medicinal qualities be subject to review and approval by the United States Food and Drug Administration (FDA).

20 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.

19 Oct 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

Study shows vitamin D, calcium supplements fail to protect against colorectal cancer

A large, randomized study at 11 U.S. hospitals including Dartmouth-Hitchcock Medical Center found that vitamin D and calcium supplements fail to protect against developing colorectal cancer.

16 Oct 2015

Medical experts launch crowd funding project to investigate effect of malaria drug on colorectal cancer

Medical experts investigating whether a common malaria drug could have a significant impact on colorectal cancer have launched a crowd funding project to fund their work.

16 Oct 2015

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.

15 Oct 2015

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Omeros Corporation today announced that it has launched OMIDRIAssure, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% for cataract surgery patients and reimbursement assistance for physicians and facilities.

15 Oct 2015

Researchers one step closer to finding effective drug for alcohol dependence

Researchers at Karolinska Institutet and the Sahlgrenska Academy in Sweden might be one step closer to finding an effective drug for alcohol dependence. In two separate studies, they show that the so-called dopamine stabilizer OSU6162 can reduce the craving for alcohol in alcohol dependent people and normalises the level of dopamine in the brain reward system of rats that have consumed alcohol over a long period of time.

14 Oct 2015

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

The Scottish Medicines Consortium has today announced that Xofigo has been accepted for use within NHS Scotland for the treatment of adult patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

13 Oct 2015

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.

13 Oct 2015

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer's disease.

12 Oct 2015

New clinical study focuses on investigational treatment to reduce impact of key protein from the brain

The Nantz National Alzheimer Center at Houston Methodist Hospital is part of a landmark clinical trial that looks at removing a key protein from the brain to prevent memory loss at least a decade before symptoms are noticed in healthy older adults.

12 Oct 2015

Placebo News and Research

Love hormone may enhance pleasure of social interactions, UCI study finds

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Common steroid medication does not reduce risk of long-term pain after heart surgery

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Major UK trial to examine role of aspirin in cancer recurrence

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Leading obesity groups stress need to regulate weight-loss dietary supplements

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

Study shows vitamin D, calcium supplements fail to protect against colorectal cancer

Medical experts launch crowd funding project to investigate effect of malaria drug on colorectal cancer

GATE opens for generic equivalent to glatiramer acetate in MS

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Researchers one step closer to finding effective drug for alcohol dependence

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

New clinical study focuses on investigational treatment to reduce impact of key protein from the brain

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News